Abstract library

14 results for "Linder Ekberg".
#1246 68 Yr Female with a Growing Inoperable Myocardial Metastase
Introduction: Two recent studies shows that cardiac metastases occur rather frequently, 13% in a population of serotoninproducing NETs(Noordzij 2014) and 4% in our own patient kohort of ileal NETs(Calissendorff 2014).
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K
#1925 SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome
Introduction: The patient is a female, 59 yrs , previously healthy except from mild allergic rinitis since 12 years of age and at 49 a suspected anaphylaxis after hazelnut intake.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD PhD Kristina Linder Ekberg
Keywords: PGD2
#138 The use of F-18-FDG-PET for patients with neuroendocrine tumors
Introduction: Neoplastic tissue exhibits high glucose utilization, which can be imaged by 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET). Whether FDG-PET is useful for neuroendocrine (NE) tumors, however, is questionable, due to the slow growth rate often observed in these tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: M.Sc. Tina Binderup
#468 mir-129-5p and Let-7 are Down-Regulated in Carcinoid Tumors
Introduction: miRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression by binding to complementary sequences on target mRNAs and their expression is often dysregulated in cancer.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Døssing
#470 Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET
Introduction: Today, grading, and thereby choice of treatment strategy for patients with neuroendocrine (NE) tumors, is mainly based on the proliferation index, Ki-67. As a supplement to this pathological evaluation, a whole body image analysis could be of value.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MSc, PhD Tina Binderup
#472 Detection of Liver Metastases and Prognostic Value of Functional and Anatomical Imaging in Patients with Neuroendocrine Tumors
Introduction: Liver metastases (LM) are frequent in patients with neuroendocrine tumors (NETs) and are associated with decreased overall survival (OS). Several treatment options are available depending on degree, localization, size and number of LM. For optimal choice of treatment and correct staging, accurate imaging modalities are crucial.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Ingrid Holst Olsen
#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients
Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Andreas Kjær
Keywords: PET, PET/CT, imaging, survival
#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen
#375 How Long to Continue Surveillance in Patients Following ‘Curative Resection’ of Primary Small Bowel Tumors?
Introduction: Around 40-50% of patients with small bowel (SB) NETs have metastatic disease at the time of presentation. The majority of the remainder proceed to surgery for attempted curative resection. The optimal duration of surveillance post ‘curative surgical’ resection of primary SB NETs is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Raj Srirajaskanthan
#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care
Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.